{"authors": [["Rotz", "Seth J", "SJ", "Division of Bone Marrow Transplantation and Immune Deficiency and."], ["Luebbering", "Nathan", "N", "Division of Bone Marrow Transplantation and Immune Deficiency and."], ["Dixon", "Bradley P", "BP", "Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH."], ["Gavriilaki", "Eleni", "E", "Bone Marrow Transplantation Unit, Hematology Department, G. Papanicolaou Hospital, Thessaloniki, Greece; and."], ["Brodsky", "Robert A", "RA", "Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD."], ["Dandoy", "Christopher E", "CE", "Division of Bone Marrow Transplantation and Immune Deficiency and."], ["Jodele", "Sonata", "S", "Division of Bone Marrow Transplantation and Immune Deficiency and."], ["Davies", "Stella M", "SM", "Division of Bone Marrow Transplantation and Immune Deficiency and."]], "text": "Transplantation-associated thrombotic microangiopathy is associated with complement activation in vitro.This data further supports the use of eculizumab for the treatment of patients with TA-TMA.", "id": "29296809", "date": "2017-08-23", "title": "In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy.", "doi": "10.1182/bloodadvances.2017008250", "journal": ["Blood advances", "Blood Adv"]}